-
1.发明公开TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CHIP 审中-公开芯片的处理（HSP70相互作用蛋白的C-末端）-BEDINGTEN疾病阻抑的天然反义转录物AGAINST芯片的
公开(公告)号：EP2467482A2
公开(公告)日：2012-06-27
申请号：EP10810639.4
申请日：2010-08-20
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K48/00 , A61K31/7088 , A61P25/00 , A61P37/00
CPC分类号： C12Q1/6823 , A61K31/7088 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12Q2600/136
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'C terminus of HSP70-Interacting Protein' (CHIP), in particular, by targeting natural antisense polynucleotides of 'C terminus of HSP70-Interacting Protein' (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.
摘要翻译： 本发明涉及，（特别地，通过靶向的CHIP'HSP70-相互作用蛋白的C末端的自然反义多核苷酸的反义寡核苷酸没有调制的“HSP70相互作用蛋白的C末端”（CHIP）的表达和/或功能 ）。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与CHIP的表达相关的疾病和病症的用途。
-
2.发明公开TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY 有权处理聚丝蛋白（FLG）-ASSOZIIERTER DISORDERS BY调制FLG表达和活性
公开(公告)号：EP2480669A2
公开(公告)日：2012-08-01
申请号：EP10819521.5
申请日：2010-09-24
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/63 , A61K31/7088 , A61K48/00
CPC分类号： C12N15/113 , A61K31/135 , A61K31/325 , A61K31/357 , A61K31/4406 , A61K31/4439 , A61K31/444 , A61K31/5415 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , A61K2300/00
摘要： The present invention relates to antisense oligonucleotides and/ or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/ or compounds and their use in treating diseases and disorders associated with the expression of FLG.
-
公开(公告)号：EP2424987A2
公开(公告)日：2012-03-07
申请号：EP10770391.0
申请日：2010-04-30
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K31/7088 , A61K48/00 , A61P19/02 , A61P31/00
CPC分类号： A61K31/7088 , C12N15/113 , C12N2310/11
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hemoglobin (HBF/HBG), in particular, by targeting natural antisense polynucleotides of Hemoglobin (HBF/HBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HBF/HBG.
摘要翻译： 本发明涉及反义寡核苷酸没有调节的表达和/或血红蛋白的功能（HBF / HBG），特别是，通过靶向血红蛋白的天然反义多核苷酸（HBF / HBG）。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与HBF / HBG表达相关的疾病和病症的用途。
-
4.发明公开TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1 有权疾病治疗的Δ-LIKE-1同系物（DLK1）ASSOCIATED阻抑的天然反义转录物AGAINST DLK1作者
公开(公告)号：EP2408920A2
公开(公告)日：2012-01-25
申请号：EP10753955.3
申请日：2010-03-16
申请人： Opko Curna, LLC
IPC分类号： C12N15/63 , C12N15/113 , C07H21/00 , A61K48/00 , C12Q1/68
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/313 , C12N2310/314 , C12N2310/315
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).
摘要翻译： 本发明涉及反义寡核苷酸没有调节和/或Delta-样（1）同系物（DLK1）的功能的表达，特别是，通过靶向Delta-样（1）同系物（DLK1）的天然反义多核苷酸。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与（DLK1）的表达相关的疾病和病症的用途。
-
5.发明公开TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF 有权治疗神经营养因子GDNF ASSOCIATED抑制BY天然反义转录反对GDNF病证
公开(公告)号：EP2396408A2
公开(公告)日：2011-12-21
申请号：EP10741791.7
申请日：2010-02-12
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N5/10 , C12N15/63
CPC分类号： C12N15/113 , C12N15/1136 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12Q1/6813 , C12N2310/111 , C12N2330/10
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.
-
6.发明公开TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP 审中-公开IQGAP（“IQ MOTIF含酶激活蛋白”）的治疗 - 相关疾病BY抑制天然反义转录反对IQGAP的
公开(公告)号：EP2470657A2
公开(公告)日：2012-07-04
申请号：EP10815846.0
申请日：2010-08-25
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K48/00 , A61K31/7088 , C12N15/63 , C12N15/52
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/3125 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/316 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/3231
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'IQ motif containing GTPase activating protein' (IQGAP), in particular, by targeting natural antisense polynucleotides of 'IQ motif containing GTPase activating protein' (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.
-
7.发明公开TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT 1 审中-公开用天然反义转录物抑制SIRT1治疗SIRT1（SIRT1）相关疾病
公开(公告)号：EP2403946A2
公开(公告)日：2012-01-11
申请号：EP10749298.5
申请日：2010-03-03
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/63 , A61K48/00
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12Y305/01098
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.
摘要翻译： 本发明涉及调节Sirtuin 1（SIRT1）表达和/或功能的反义寡核苷酸，特别是通过靶向Sirtuin 1的天然反义多核苷酸（SIRT1）。 本发明还涉及鉴定这些反义寡核苷酸及其在治疗与SIRT1表达相关的疾病和病症中的用途。
-
8.发明公开TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1 审中-公开抗衰老酶1处理（SIRT1）-BEDINGTEN病从天然反义转录针对抗衰老酶抑制1
公开(公告)号：EP2370580A2
公开(公告)日：2011-10-05
申请号：EP09831068.3
申请日：2009-12-02
申请人： Opko Curna, LLC
IPC分类号： C12N15/63 , C12N15/11 , C07H19/00 , A61K31/712 , C12Q1/68
CPC分类号： A61K31/712 , C12N15/1137 , C12N2310/11 , C12Y305/01098 , Y10T436/143333
摘要： Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.
-
9.发明公开TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2 有权治疗核因子（红细胞衍生） - 样2（NRF2）有关抑制BY天然反义转录反对NRF2病证
公开(公告)号：EP2408919A2
公开(公告)日：2012-01-25
申请号：EP10753950.4
申请日：2010-03-16
申请人： Opko Curna, LLC
IPC分类号： C12N15/63 , C12N15/113 , C07H21/00 , A61K48/00 , C12Q1/68
CPC分类号： C12N15/113 , C12N2310/113 , C12N2310/14 , C12N2310/312 , C12N2310/313 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Q1/6876 , C12Q2600/136 , C12Q2600/178 , G01N25/04
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
-
10.发明公开TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF 有权治疗脑源性神经营养因子（BDNF）的可通过抑制天然反义转录反对BDNF的疾病
公开(公告)号：EP2396038A2
公开(公告)日：2011-12-21
申请号：EP10741789.1
申请日：2010-02-12
申请人： Opko Curna, LLC
CPC分类号： C12N15/1136 , A61K31/7088 , A61K45/06 , A61K48/00 , C12N2310/11 , C12N2310/113 , C12N2310/315 , C12N2320/30 , C12N2330/10 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/74 , G01N2333/48 , G01N2500/02
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.019 秒)
